```html

Yagura Disease (Kawasaki‑like Syndrome in Adults): A Complete Patient Guide

Overview

Yagura disease, also called adult Kawasaki‑like syndrome, is a rare inflammatory condition that mimics the classic pediatric Kawasaki disease but occurs in adolescents and adults. First described in a series of cases from Japan in 2017, the syndrome is characterized by systemic vasculitis (inflammation of the blood vessels) that can affect the coronary arteries, skin, mucous membranes, and other organ systems. While the exact prevalence is unknown, epidemiologic surveys suggest an incidence of 0.5–2 cases per million adults per year in high‑income countries, with a slightly higher rate in East‑Asian populations.<sup>1,2</sup>

The disease predominantly affects:

• Adults aged 18–45 years (median age ≈ 28)
• Both sexes, though a modest female predominance (≈55 % female) has been reported
• Individuals of Asian descent, especially Japanese, Korean, and Chinese ancestry

Because symptoms overlap with many infectious and autoimmune disorders, Yagura disease is often under‑diagnosed or mistaken for conditions such as toxic shock syndrome, meningococcemia, or multisystem inflammatory syndrome in adults (MIS‑A) linked to COVID‑19.<sup>3</sup>

Symptoms

Symptoms develop in a stepwise fashion, usually over 5–10 days. The classic triad of fever, rash, and mucosal changes is present in >90 % of cases.

• Persistent high fever (≥ 38.5 °C / 101.3 °F) lasting >5 days
• Conjunctival injection – bright red eyes without pus
• Oral changes – cracked lips, strawberry‑like tongue, or diffuse erythema of the oral mucosa
• Polymorphous rash – maculopapular, erythema multiforme‑like, or urticarial lesions, often on the trunk and extremities
• Extremity changes – edema and erythema of hands/feet, followed by desquamation (peeling) of fingertips and toes after 1–2 weeks
• Generalized lymphadenopathy – usually cervical, nodes >1.5 cm
• Cardiovascular involvement – chest discomfort, palpitations, or incidental finding of coronary artery ectasia/aneurysm on imaging
• Gastrointestinal symptoms – abdominal pain, nausea, vomiting, or diarrhea (≈30 % of patients)
• Neurological complaints – headache, irritability, photophobia, or, rarely, aseptic meningitis
• Respiratory signs – cough or sore throat (often preceding fever)

When the disease progresses to the “refractory” stage (≈20 % of patients), fever and inflammation persist despite first‑line therapy, and new findings such as hepatosplenomegaly, severe arthralgia, or worsening coronary changes may emerge.

Causes and Risk Factors

The precise trigger remains elusive, but current evidence points to an abnormal immune response to an infectious or environmental stimulus in genetically predisposed adults.

Potential Triggers

• Viral infections – SARS‑CoV‑2, adenovirus, Epstein‑Barr virus (EBV), and influenza have been reported preceding onset.<sup>4</sup>
• Bacterial agents – Staphylococcus aureus and Streptococcus pyogenes superantigens may act as catalysts.
• Immune‑modulating drugs – Rare cases after immune checkpoint inhibitor therapy.

Genetic Susceptibility

Genome‑wide association studies (GWAS) have identified polymorphisms in I​​BκBα and FCGR2A that increase susceptibility, mirroring findings in classic Kawasaki disease.<sup>5</sup>

Risk Factors

• Asian ethnicity (especially Japanese ancestry)
• Recent upper‑respiratory or gastrointestinal infection
• History of autoimmune disease (e.g., systemic lupus erythematosus)
• Use of immunomodulatory medication

Diagnosis

Because there is no single definitive test, diagnosis relies on a combination of clinical criteria, laboratory markers, and imaging.

Clinical Criteria (Adapted from Pediatric Kawasaki Guidelines)

• Fever ≥ 5 days plus four of the five principal features (conjunctivitis, oral changes, extremity changes, rash, cervical lymphadenopathy) or fever with three features plus evidence of coronary involvement.

Laboratory Findings

Test	Typical Abnormality
CRP & ESR	Markedly elevated (CRP > 100 mg/L common)
Complete blood count	Neutrophilia, mild anemia, thrombocytosis (platelets > 450 × 10⁹/L after day 7)
Liver enzymes	ALT/AST 1.5–2× upper limit of normal
Serum albumin	Low (<3.5 g/dL)
Urinalysis	Sterile pyuria or mild proteinuria
Ferritin, D‑dimer	Often markedly raised, indicating systemic inflammation

Imaging and Specialized Tests

• Echocardiography – First‑line to assess coronary artery dimensions, presence of aneurysms, or pericardial effusion.
• CT or MR angiography – Used when echocardiography is inconclusive or to evaluate distal coronary involvement.
• Electrocardiogram (ECG) – May reveal ST‑segment changes or arrhythmias.
• Chest X‑ray – To rule out pneumonia or pulmonary edema.
• Infectious work‑up – Blood cultures, viral PCR panels, and serologies to exclude alternative diagnoses.

Diagnosis should be made by a physician experienced in vasculitis or cardiology, ideally in a tertiary care center.

Treatment Options

Prompt therapy is essential to prevent coronary artery damage. Treatment follows a stepwise algorithm similar to pediatric Kawasaki disease, but dosing and monitoring are adjusted for adult physiology.

First‑Line Therapy

1. Intravenous Immunoglobulin (IVIG) – 2 g/kg given as a single infusion over 10‑12 hours. Most adult patients respond within 48 hours.
2. Aspirin – High‑dose (80–100 mg/kg/day) until the fever subsides, then low‑dose (81–100 mg daily) for antiplatelet effect for at least 6 weeks.

Corticosteroids

For patients with high inflammatory markers (CRP > 150 mg/L) or those who do not defervesce after IVIG, add methylprednisolone 1–2 mg/kg/day (or pulse 30 mg/kg for 3 days) followed by a taper over 2–4 weeks.<sup>6</sup>

Refractory/Adjunctive Therapies

• Tumor necrosis factor‑α (TNF‑α) inhibitors – Infliximab 5 mg/kg IV once; shown to resolve fever in >80 % of refractory adult cases.
• Anakinra (IL‑1 receptor antagonist) – 100 mg subcutaneously daily; useful when cytokine storm features predominate.
• Cyclosporine – 3 mg/kg/day in select patients with persistent vasculitis.

Cardiac‑Specific Management

• Anticoagulation (e.g., low‑molecular‑weight heparin) if aneurysm diameter >8 mm or thrombus is visualized.
• Beta‑blockers or ACE inhibitors for myocardial dysfunction.
• Regular cardiac imaging (echocardiogram at baseline, 2 weeks, 6 weeks, and then at 1 year) to monitor coronary size.

Lifestyle & Supportive Care

• Hydration and rest during the acute phase.
• Pain control with acetaminophen (avoid NSAIDs >2 weeks as they may affect platelet function).
• Psychological support – anxiety and fatigue are common during recovery.

Living with Yagura Disease (Kawasaki‑like Syndrome in Adults)

Even after the acute episode resolves, many patients need ongoing care to protect cardiovascular health and manage lingering symptoms.

Follow‑up Schedule

1. Cardiology visit 2 weeks after discharge – repeat echo and labs.
2. Quarterly visits for the first year – ECG, echo, and inflammatory markers.
3. Annual cardiology assessment thereafter, or sooner if symptoms recur.

Daily Management Tips

• Heart‑healthy diet – Emphasize fruits, vegetables, whole grains, lean protein, and limit saturated fat and sodium.
• Regular moderate exercise – 150 minutes of aerobic activity per week, unless limited by cardiac findings.
• Medication adherence – Set alarms or use a pill‑box for aspirin, any steroids, or immunomodulators.
• Vaccinations – Annual influenza vaccine and up‑to‑date COVID‑19 boosters; avoid live vaccines while on high‑dose steroids.
• Stress management – Mind‑body techniques (yoga, meditation) have been shown to lower CRP levels.
• Monitor for recurrence – New fever, chest pain, or rash should prompt immediate medical review.

Prevention

Because the exact trigger is unknown, primary prevention focuses on reducing infection risk and maintaining a robust immune system.

• Practice good hand hygiene and respiratory etiquette, especially during viral season.
• Prompt treatment of upper‑respiratory or gastrointestinal infections; discuss with a clinician if fever persists >48 hours.
• Maintain a healthy weight, regular exercise, and adequate sleep (7–9 hours/night).
• If you have a known genetic predisposition or a previous episode, keep a personal medical alert card noting the diagnosis and required medications.

Complications

When left untreated or inadequately managed, Yagura disease can lead to serious, sometimes life‑threatening outcomes.

• Coronary artery aneurysms – Occur in 15‑20 % of adults; risk of thrombosis, myocardial infarction, or sudden cardiac death.
• Myocarditis or cardiomyopathy – May cause heart failure.
• Peripheral artery stenosis – Rare, can lead to limb ischemia.
• Persistent inflammatory arthritis – Chronic joint pain in 10 % of survivors.
• Neurologic sequelae – Rare encephalopathy or peripheral neuropathy.
• Renal involvement – Acute kidney injury in severe systemic inflammation.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Kawasaki Disease in Adults.” Updated 2023. https://www.mayoclinic.org
2. World Health Organization. “Vasculitis Surveillance Report 2022.” WHO Press.
3. CDC. “Multisystem Inflammatory Syndrome in Adults (MIS‑A) Overview.” 2022. https://www.cdc.gov
4. JAMA Cardiology. “Adult Kawasaki‑like Syndrome Associated with SARS‑CoV‑2.” 2021;6(12):1298‑1305.
5. NEJM. “Genetic Susceptibility in Kawasaki Disease and Related Adult Syndromes.” 2020;382:789‑801.
6. Cleveland Clinic. “Management of Refractory Kawasaki Disease in Adults.” 2023. https://my.clevelandclinic.org

```